This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
48. After regulation 46(2) (labelling of investigational medicinal products)(1) insert—
“(3) Paragraph (1) does not apply to a POC investigational medicinal product that is to be administered in its entirety immediately after manufacture.”.
There are amendments but none is relevant.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
